BCKDK

Across TCGA pan-cancer cohorts, BCKDK mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BCKDK data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BCKDK mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCKDK expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

CCRCC, UCEC, and LSCC are the cancer types where BCKDK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.458	0.913	.005	16	view →
UCEC	DFS	Median	All	0.771	0.938	.012	14	view →
LSCC	OS	Tertile	II,III,IV	0.998	0.735	.007	11	view →
HNSC	OS	Median	II,III,IV	0.993	0.933	.027	3	view →
GBM	OS	Quartile	All	0.890	0.980	.029	2	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.443	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BCKDK–CCRCC (DFS)

Open the CCRCC breakdown →